Genetic Exposé Of Ovarian Cancer Prompts Radical Rethink Of Trial Design
This article was originally published in Pharmaceutical Approvals Monthly
Whereas Phase III cancer trials are currently randomized and involve hundreds of patients, some experts say small trials with from 20 to 50 patients make more sense for targeted drugs in ovarian cancer, considering the genetic diversity of this already uncommon disease.
You may also be interested in...
Looking ahead to the upcoming American Society of Clinical Oncology meeting, analysts flag abstracts on PD-1+PD-L1 combination data from AstraZeneca and studies in areas of high unmet need, like ovarian and pancreatic cancers, and EGFR-positive, T790-mutated lung cancer.
Hopes for IGF-1R inhibitor ganitumab had not been high due to past flops for others in the class. But research in extensive stage small-cell lung cancer and KRAS wild-type metastatic colorectal cancer goes on, at least for now.
Astra Zeneca hustles on genomic analyses of PARP inhibitor olaparib after drug fails to improve overall survival in a Phase II ovarian cancre trial, which could signify a revival. Meanwhile, Avastin lead investigator defends anti-angiogenesis approach, considering tremendous diversity of the relatively uncommon disease.